Laboratory Publications
Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study - Archive ouverte HAL
Article Dans Une Revue Rheumatology and Therapy Année : 2020

Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study

Dates et versions

hal-05001626 , version 1 (22-03-2025)

Identifiants

Citer

Pascal Hilliquin, Thomas Barnetche, Athan Baillet, René-Marc Flipo, Eric Lespessailles, et al.. Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study. Rheumatology and Therapy, 2020, 8 (1), pp.95-108. ⟨10.1007/s40744-020-00253-0⟩. ⟨hal-05001626⟩
25 Consultations
0 Téléchargements

Altmetric

Partager

  • More